期刊文献+

慢性粒细胞白血病骨髓细胞的SFRP2基因启动子高甲基化 被引量:3

Hypermethylation in SFRP2 promoter in human leukemia K562 cells and bone marrow specimen with chronic myeloid leukemia
下载PDF
导出
摘要 目的研究慢性粒细胞白血病(chronic myeloid leukemia,CML)骨髓细胞SFRP2基因启动子甲基化状态,探讨SFRP2基因启动子甲基化在CML发病机制中的作用。方法分别采用RT-PCR、甲基化特异性PCR(methylation-specif-ic PCR,MSP)方法检测CML细胞系K562细胞及骨髓标本SFRP2 mRNA及SFRP2基因启动子CpG岛甲基化状态;并予DNA甲基化转移酶抑制剂5-氮杂-2’-脱氧胞苷(Aza)联合组蛋白去乙酰化酶抑制剂曲古菌素A(TSA)处理K562细胞,观察其SFRP2 mRNA表达情况。结果 SFRP2 mRNA在K562细胞、CML和正常人骨髓标本表达率分别为0、22%(4/18)、100%(8/8)(P<0.05);SFRP2基因启动子甲基化率在K562细胞、CML和正常人骨髓标本分别为100%、66%(25/38)、0(0/13)(P<0.05);伴随K562细胞去甲基化药物处理后未甲基化序列的增加,其SFRP2 mRNA恢复了表达。结论 CML骨髓细胞的SFRP2基因启动子存在高甲基化现象,SFRP2基因启动子甲基化可能是CML发生发展的分子机制之一,提示了其甲基化可能成为CML的新的参考标记物。 Objective To determine the methylation status of secreted frizzled-related protein 2(SFRP2) gene in chronic myeloid leukemia(CML) bone marrow cells,and try to find the role of its promoter methylation during the tumorigenesis of CML.Methods The expression of SFRP2 in CML cell line K562,bone marrow specimens of identified CML patients and health volunteers were detected with semi-quantitative PCR(RT-PCR).The methylation status of SFRP2 promoter was detected in K562 cells and CML bone marrow specimens by methylation-specific PCR(MSP).After K562 cells was treated with pharmacological demethylation 5-aza-2'deoxycytidine(Aza) and trichostatin A(TSA),the expression of SFRP2 was detected again with RT-PCR.Results SFRP2 was silenced in K562 cells,expressed in 22.0%(4/18) CML bone marrow specimens,and detected in all normal bone marrow samples(100.0%,8/8,P0.05).The frequencies of SFRP2 promoter methylation were 100%,66%(25/38) and 0(0/13) respectively in K562 cells,CML bone marrow and normal bone marrow specimens(P0.05).Pharmacological demethylation treatment dramatically induced mRNA expression of SFPR2,and this reactivation was associated with an increase of unmethylation alleles.Conclusion The promoter of SFRP2 gene are hypermethylated in CML,which be one of the molecular mechanisms of CML.Its hypermethylation might serve as a new biomarker for CML.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2011年第24期2583-2586,共4页 Journal of Third Military Medical University
关键词 慢性粒细胞白血病 SFRP2 甲基化 去甲基化 chronic myeloid leukemia secreted frizzled-related protein 2 methylation demethylation
  • 相关文献

参考文献6

二级参考文献105

  • 1JianQi You-QingZhu Mei-FangHuang DongYang.Hypermethylation of CpG island in O^6-methylguanine-DNA methyltransferase gene was associated with K-rasG to A mutation in colorectal tumor[J].World Journal of Gastroenterology,2005,11(13):2022-2025. 被引量:2
  • 2唐卫中,高枫,李卫,唐宗江.结直肠癌APC、K-ras、p53基因突变检测[J].肿瘤,2006,26(3):282-284. 被引量:16
  • 3NUSSE R, VARMUS H E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome[J]. Cell, 1982, 31 (1) : 99-109. 被引量:1
  • 4WODARZ A, NUSSE R. Mechanisms of Wnt signaling in development[J]. Annu Rev Cell Dev Biol, 1998, 14: 59-88. 被引量:1
  • 5MOON RT, BOWERMAN B, BOUTROS M, et al. The promise and perils of Wnt signaling through beta-catenin [ J ]. Science, 2002, 296(5573) : 1644-1646. 被引量:1
  • 6AKIYAMA T. Wnt/β-catenin signaling[ J]. Cytokine Growth Factor Rev, 2000, 11(4) : 273-282. 被引量:1
  • 7MLODZIK M. Planar cell polarization: do the same mechanisms regulate Drosophila tissue polarity and vertebrate gastrulation? [J]. Trends Genet, 2002, 18(11) :564-571. 被引量:1
  • 8KUHL, SHELDAHL LC, PARK M, et al. The Wnt/Ca^2+ pathway: a new vertebrate Wnt signaling pathway takes shape [ J]. Trends Genet, 2000, 16(7) :279-283. 被引量:1
  • 9CHEN A E, GINTT D D, FAN C M. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins [ J ]. Nature, 2005, 433 (7023) :317-322. 被引量:1
  • 10LOGAN C Y, NUSSE R. The Wnt signaling pathway in development and disease[J]. Annu Rev Cell Dev Biol, 2004, 20:781- 810. 被引量:1

共引文献83

同被引文献47

  • 1王刚,刘利,陈杰,辛海明,张晓兵,蔡云,侯露,郭乔楠,刘泽军.白血病细胞雄激素受体基因启动子甲基化状态的研究[J].第三军医大学学报,2007,29(10):932-934. 被引量:5
  • 2王东海,王洋,王敏,刘航,徐智芳,饶青,孟继虹,王建祥.pig7基因在急性白血病细胞中的表达及其临床意义[J].中华血液学杂志,2007,28(8):532-536. 被引量:2
  • 3Deiniger MW, Goldman JM, Melo JV, et al. The molecular biol ogy of chronic myeloid leukemia[J]. Blood, 2010, 96(3): 343- 56. 被引量:1
  • 4Cortes JE, Jones D, O' Brien S, et al. Nilotinib as front line treatment for patients with chronic myeloid leukemia [J]. J Clin Oncol, 2010, 28: 392-7. 被引量:1
  • 5Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of Euro- pean Leukemia Net[J]. J Clin Oncol, 2009, 27:6041-51. 被引量:1
  • 6Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR- ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase[J]. J Clin Oncol, 2009, 27: 4204-10. 被引量:1
  • 7Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the front- line of Ph(+) chronic myeloid leukemia[J]. Blood, 2009, 114: 4933-8. 被引量:1
  • 8Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronie phase chronic myeloid leukemia: analysis of responses ac- cording to preexisting BCR-ABL mutations [J]. Blood, 2009, 114, 4944-53. 被引量:1
  • 9White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib[J]. J Clin Oneol, 2010, 28: 2761-7. 被引量:1
  • 10Oehler VG, Yeung KY, Choi YE, et al. The derivation of diag- lostic markers of chronic myeloid leukemia progression from miroarraydata[J]. Blood, 2009, 114: 3292-8. 被引量:1

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部